ArticleScience, technology & human values2010
National Biobanks: Clinical Labor, Risk Production, and the Creation of Biovalue.
Article in Science, technology & human values, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Bigger than sport: the enhanced games and the commodification of telehealth, testosterone, and dependency.Harm reduction journal · 2025Article
- The Fortunes of Genomic Medicine: A Quarter Century of Promise.Annals of human genetics · 2025Article
- How the world of biobanking is changing with artificial intelligence.Frontiers in digital health · 2025Review
- Conceptualizing the public good for genomics in the global South: a cross-disciplinary roundtable dialogue.Frontiers in genetics · 2025Review
- Synthetic Health Data: Real Ethical Promise and Peril.The Hastings Center report · 2024Article
- Contributing to an autism biobank: Diverse perspectives from autistic participants, family members and researchers.Autism : the international journal of research and practice · 2024Article
- Risk mapping for better governance in biobanking: the case of biobank.cy.Frontiers in genetics · 2024Article
- Between data providers and concerned citizens: Exploring participation in precision public health in Switzerland.Public understanding of science (Bristol, England) · 2024Article
- The Temporal Politics of Placenta Epigenetics: Bodies, Environments and Time.Body & society · 2023Article
- Drivers and constraints to environmental sustainability in UK-based biobanking: balancing resource efficiency and future value.BMC medical ethics · 2023Article
- Precision public health in the making: examining the becoming of the "social" in a Swiss environmental health population-based cohort.Frontiers in sociology · 2023Article
- Exploring how biobanks communicate the possibility of commercial access and its associated benefits and risks in participant documents.BMC medical ethics · 2022Article
- Better governance starts with better words: why responsible human tissue research demands a change of language.BMC medical ethics · 2022Article
- Value-creation in the health data domain: a typology of what health data help us do.BioSocieties · 2022Article
- The social licence for data-intensive health research: towards co-creation, public value and trust.BMC medical ethics · 2021Review
- Obligations of the "Gift": Reciprocity and Responsibility in Precision Medicine.The American journal of bioethics : AJOB · 2021Article
- An agenda-setting paper on data sharing platforms: euCanSHare workshop.Open research Europe · 2021Article
- The reconfiguration of biobanks in Europe under the BBMRI-ERIC framework: towards global sharing nodes?Life sciences, society and policy · 2020Article
- Accomplishing an adaptive clinical trial for cancer: Valuation practices and care work across the laboratory and the clinic.Social science & medicine (1982) · 2020Article
- From waste product to blood, brains and narratives: developing a pluralist sociology of contributions to health research.Sociology of health & illness · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The development of genomics has dramatically expanded the scope of genetic research, and collections of genetic biosamples have proliferated in countries with active genomics research programs. In this essay, we consider a particular kind of collection, national biobanks. National biobanks are often presented by advocates as an economic "resource" that will be used by both basic researchers and academic biologists, as well as by pharmaceutical diagnostic and clinical genomics companies. Although national biobanks have been the subject of intense interest in recent social science literature, most prior work on this topic focuses either on bioethical issues related to biobanks, such as the question of informed consent, or on the possibilities for scientific citizenship that they make possible. We emphasize, by contrast, the economic aspect of biobanks, focusing specifically on the way in which national biobanks create biovalue. Our emphasis on the economic aspect of biobanks allows us to recognize the importance of what we call clinical labor-that is, the regularized, embodied work that members of the national population are expected to perform in their role as biobank participants-in the creation of biovalue through biobanks. Moreover, it allows us to understand how the technical way in which national biobanks link clinical labor to databases alters both medical and popular understandings of risk for common diseases and conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.